Clinical Trial Update: Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies [Phase 2]

View source ↗

Summary

A Phase 2 extension study update for subjects previously enrolled in triheptanoin studies in long-chain fatty acid oxidation disorders, with completed status an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carnitine Palmitoyltransferase Deficiency
• Carnitine Palmitoyltransferase Ii Deficiency
• Carnitine-acylcarnitine Translocase Deficiency
• Long-chain 3-hydroxy-acyl-coa Dehydrogenase Deficiency
• Trifunctional Protein Deficiency
• Very Long-chain Acyl-coa Dehydrogenase Deficiency

Drugs mentioned

• Triheptanoin (triheptanoin)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2021-12-08